Repligen Q4 Revenue Climbs 18.1% to $197.9M, EPS Tops by 10.4%
Repligen posted fourth-quarter CY2025 revenue of $197.9 million, up 18.1% year-over-year, beating consensus by 2.7%, and delivered non-GAAP EPS of $0.49, 10.4% above estimates. It forecast 2026 revenue of $810 million to $840 million, implying 10%–14% growth, and expects adjusted operating margin expansion of 150 basis points.
1. Q4 CY2025 Performance
Repligen generated revenue of $197.9 million in Q4 CY2025, an 18.1% increase year-over-year and 14% organic growth. Adjusted operating margin rose to 15% and non-GAAP EPS reached $0.49, beating consensus estimates by 10.4%.
2. 2026 Guidance
Management provided 2026 revenue guidance of $810 million to $840 million, representing 10%–14% growth, and projected an adjusted operating margin expansion of 150 basis points driven by operational efficiencies.
3. Strategic Initiatives
During Q4, the company launched three new high-performance chromatography resins—AVIPure HiPer™ AAV9, AAV8 affinity resins and HiPer™ QA anion exchange resin—and expanded its presence with a new office in Singapore and footprint extension in Japan.